Update on Meningococcal A Vaccine Development and Introduction
General Info
This presentation, delivered at the WHO Product Development for Vaccines Advisory Committee (PD-VAC) meeting, 7-9 September 2015, provides an update from the Meningitis Vaccine Project (MVP), a collaboration between the WHO and PATH dedicated to eliminating epidemic meningitis in sub-Saharan Africa. It covers the introduction and rollout in 26 countries of MenAfriVac, a vaccine developed by the project to protect infants of less than a year to people up to 29 years of age in the African meningitis belt against meningococcal bacterium Neisseria meningitidis group A.
Citation
Preziosi MP, Department of Immunization, Vaccines, and Biologicals (World Health Organization). Update on Meningococcal A Vaccine Development and Introduction. Presented at: WHO Product Development for Vaccines Advisory Committee Meeting (PD-VAC); 2015 Sep 7-9; Geneva, Switzerland.